Abstract:Abstract Background Alternative splicing isoforms have been reported as a new and robust class of diagnostic biomarkers. Over 95% of human genes are estimated to be alternatively spliced as a powerful means of producing functionally diverse proteins from a single gene. The emergence of next-generation sequencing technologies, especially RNA-seq, provides novel insights into large-scale detection and analysis of alternative splicing at the transcriptional level. Advances in Proteomic Technologies such as liquid chromatography coupled tandem mass spectrometry (LC–MS/MS), have shown tremendous power for the parallel characterization of large amount of proteins in biological samples. Although poor correspondence has been generally found from previous qualitative comparative analysis between proteomics and microarray data, significantly higher degrees of correlation have been observed at the level of exon. Combining protein and RNA data by searching LC–MS/MS data against a customized protein database from RNA-Seq may produce a subset of alternatively spliced protein isoform candidates that have higher confidence. Results We developed a bioinformatics workflow to discover alternative splicing biomarkers from LC–MS/MS using RNA-Seq. First, we retrieved high confident, novel alternative splicing biomarkers from the breast cancer RNA-Seq database. Then, we translated these sequences into in silico Isoform Junction Peptides , and created a customized alternative splicing database for MS searching. Lastly, we ran the Open Mass spectrometry Search Algorithm against the customized alternative splicing database with breast cancer plasma proteome. Twenty six alternative splicing biomarker peptides with one single intron event and one exon skipping event were identified. Further interpretation of biological pathways with our Integrated Pathway Analysis Database showed that these 26 peptides are associated with Cancer, Signaling, Metabolism, Regulation, Immune System and Hemostasis pathways, which are consistent with the 256 alternative splicing biomarkers from the RNA-Seq. Conclusions This paper presents a bioinformatics workflow for using RNA-seq data to discover novel alternative splicing biomarkers from the breast cancer proteome. As a complement to synthetic alternative splicing database technique for alternative splicing identification, this method combines the advantages of two platforms: mass spectrometry and next generation sequencing and can help identify potentially highly sample-specific alternative splicing isoform biomarkers at early-stage of cancer.

Computational Identification of Specific Splicing Regulatory Elements from RNA-seq in Lung Cancer.

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Computational Identification of Tissue-Specific Splicing Regulatory Elements in Human Genes from RNA-Seq Data

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Exploring The Effect Of Differentially Expressed Long Non-Coding Rnas Driven By Copy Number Variation On Competing Endogenous Rna Network By Mining Lung Adenocarcinoma Data

Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets

Deciphering Associations Between Three RNA Splicing-Related Genetic Variants and Lung Cancer Risk

Genome and Transcriptome Sequencing of Lung Cancers Reveal Diverse Mutational and Splicing Events

Identification of novel alternative splicing biomarkers for breast cancer with LC/MS/MS and RNA-Seq

Integrated Analysis of a Compendium of RNA-Seq Datasets for Splicing Factors.

Splicing inhibition mediated by reduced splicing factors and helicases is associated with the cellular response of lung cancer cells to cisplatin

Identification of alternative splicing associated with clinical features: from pan-cancers to genitourinary tumors

RNA-binding protein CELF6 modulates transcription and splicing levels of genes associated with tumorigenesis in lung cancer A549 cells

Genome-wide identification of pan-cancer common and cancer-specific alternative splicing events in 9 types of cancer

Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung adenocarcinoma

Systematic Identification of Cancer-Related Long Noncoding RNAs and Aberrant Alternative Splicing of Quintuple-Negative Lung Adenocarcinoma Through RNA-Seq

Clinically relevant immune subtypes based on alternative splicing landscape of immune-related genes for lung cancer advanced PPPM approach

Detecting Tissue-Specific Regulation of Alternative Splicing As a Qualitative Change in Microarray Data.

Systematic identification of regulatory variants associated with cancer risk

Machine learning-optimized targeted detection of alternative splicing

Improved methods for RNAseq-based alternative splicing analysis